Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Research & Development: 2017-2025

Historic Research & Development for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to $13.2 million.

  • Organogenesis Holdings' Research & Development rose 27.81% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.8 million, marking a year-over-year decrease of 9.35%. This contributed to the annual value of $50.3 million for FY2024, which is 13.27% up from last year.
  • Organogenesis Holdings' Research & Development amounted to $13.2 million in Q3 2025, which was up 27.19% from $10.4 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' Research & Development registered a high of $15.6 million during Q2 2024, and its lowest value of $6.2 million during Q1 2021.
  • Moreover, its 3-year median value for Research & Development was $11.2 million (2023), whereas its average is $11.7 million.
  • Per our database at Business Quant, Organogenesis Holdings' Research & Development soared by 141.39% in 2021 and then slumped by 33.31% in 2025.
  • Over the past 5 years, Organogenesis Holdings' Research & Development (Quarterly) stood at $8.3 million in 2021, then surged by 37.95% to $11.4 million in 2022, then climbed by 3.29% to $11.8 million in 2023, then declined by 2.04% to $11.5 million in 2024, then rose by 27.81% to $13.2 million in 2025.
  • Its last three reported values are $13.2 million in Q3 2025, $10.4 million for Q2 2025, and $10.6 million during Q1 2025.